Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.91 USD | +11.11% | +13.86% | +219.45% |
Financials (USD)
Sales 2024 * | 14.77M | Sales 2025 * | 12.14M | Capitalization | 2.76B |
---|---|---|---|---|---|
Net income 2024 * | -292M | Net income 2025 * | -326M | EV / Sales 2024 * | 187 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 228 x |
P/E ratio 2024 * |
-8.99
x | P/E ratio 2025 * |
-8.49
x | Employees | 253 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
Latest transcript on Avidity Biosciences, Inc.
1 day | +11.11% | ||
1 week | +13.86% | ||
Current month | +19.81% | ||
1 month | +20.01% | ||
3 months | +113.99% | ||
6 months | +364.04% | ||
Current year | +219.45% |
Managers | Title | Age | Since |
---|---|---|---|
Troy Wilson
FOU | Founder | 55 | 12-11-12 |
Sarah Boyce
CEO | Chief Executive Officer | 52 | 19-09-30 |
Michael MacLean
DFI | Director of Finance/CFO | 58 | 20-05-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arthur Levin
BRD | Director/Board Member | 70 | 13-09-30 |
Carsten Boess
BRD | Director/Board Member | 57 | 20-04-12 |
Edward Kaye
BRD | Director/Board Member | 74 | 19-08-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - | |
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 28.91 | +11.11% | 1,798,074 |
24-05-13 | 26.02 | +0.23% | 783,775 |
24-05-10 | 25.96 | -4.21% | 1,162,942 |
24-05-09 | 27.1 | +3.99% | 1,235,116 |
24-05-08 | 26.06 | +2.64% | 804,094 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+219.45% | 2.76B | |
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-12.32% | 33.03B | |
+52.41% | 24.68B | |
-17.39% | 15.12B | |
-9.14% | 12.81B | |
-10.48% | 11.79B | |
-42.45% | 11.64B | |
+6.14% | 8.9B |
- Stock Market
- Equities
- RNA Stock